Quantcast

Industry news that matters to you.  Learn more

Recently Identified Biomarker Could Be Valid Diagnostic Tool for Gaucher Disease, Mouse Study Suggests

Glucosylsphingosine (lyso-Gb1), a recently identified biomarker for Gaucher disease (GD), was shown to contribute to the development or peripheral symptoms in a mouse study, potentially validating its use as a diagnostic tool, according to new research. The study, “Glucosylsphingosine Causes Hematological and Visceral Changes in Mice—Evidence for a Pathophysiological Role in Gaucher Disease,” was published in the International Journal of Molecular Sciences.

Meso Scale Discovery Launches New V-PLEX Assays for Th17 Research

Meso Scale Discovery, a division of Meso Scale Diagnostics, LLC. (MSD), recently launched V-PLEX® immunoassays validated for the detection of the biomarkers IL-17A, IL-21, IL-22, IL-23, IL-27, and MIP-3α in human cell culture supernatants, serum, plasma, and urine.

Tau Shalt Not Return to Play

This January, former New York Jets defensive end Mark Gastineau told a radio show host that he had been diagnosed with dementia, Alzheimer’s Disease, and Parkinson’s Disease. The Jets all-time leader in sacks said he believes his ailments were caused by playing football. The revelations came just a few weeks before the Super Bowl, the most widely viewed event in sports.

Utility Of Rubicon Genomics’ ThruPLEX-FD Kit Validated In Study Showing “Liquid Biopsy” Can Track Genomic Evolution Of Cancer In Response To Therapy

Rubicon Genomics, Inc., a leader in the development and commercialization of innovative sample-specific nucleic acid library preparation products used in research and clinical testing, recently reported that its ThruPLEXTM-FD Prep Kits contributed to the success of a breakthrough study recently published in Nature1 that showed that genomic data extracted from the plasma of cancer patients can be used to track drug resistance and potentially guide treatment.

Sanofi Announces Upcoming Launch of MyStar Extra, the First Self-Monitoring Blood Glucose Meter With Estimated A1c

At the annual meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain, Sanofi (EURONEXT : SAN and NYSE : SNY) recently presented the innovative blood glucose meter MyStar Extra®, the first self-monitoring device that provides robust estimates of the A1c value, a key indicator for long-term glucose control.[3],[4] The hemoglobin A1C (HbA1C) assay has become the cornerstone for the assessment of diabetes control and A1c test results are widely used to guide treatment decisions.[5],[6] Especially convenient for people starting on insulin or using insulin, MyStar Extra® is a supportive meter, designed to help people with diabetes be engaged in their insulin management and treatment plan.[7],[8],[9]